Immunosuppressive effects of clozapine and haloperidol: Enhanced production of the interleukin-1 receptor antagonist

Schizophrenia Research

Volumn 42, Issue 2, 2000, Pages 157-164

  Song, Cai ^a,b   Lin, Ai hua ^a   Kenis, Gunter ^c,d   Bosmans, Eugene ^c   Maes, Michael ^a,e,f,g,h  

^a Clinical Research Center for Mental Health of Antwerp   (Belgium)

^b CARLETON UNIVERSITY   (Canada)

^c Eurogenetics   (Belgium)

^d DEPARTMENT OF CARDIOLOGY   (Belgium)

^e IRCCS ISTITUTO CENTRO SAN GIOVANNI DI DIO FATEBENEFRATELLI   (Italy)

^f VANDERBILT UNIVERSITY   (United States)

^g MAASTRICHT UNIVERSITY   (Netherlands)

^h MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cytokines; IL 1RA; Immunosuppression; Neuroleptics; Schizophrenia

Indexed keywords

CLOZAPINE; CYTOKINE; GAMMA INTERFERON; HALOPERIDOL; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 6;

ADULT; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; IMMUNOMODULATION; LYMPHOCYTE PROLIFERATION; MALE; NORMAL HUMAN; PRIORITY JOURNAL;

ADULT; ANTIPSYCHOTIC AGENTS; CLOZAPINE; FEMALE; HALOPERIDOL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON TYPE II; MALE; RECEPTORS, INTERLEUKIN-1; RECEPTORS, INTERLEUKIN-6; SCHIZOPHRENIA;

EID: 0034615859     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0920-9964(99)00116-4     Document Type: Article

References (42)

1. Aymard N., Baldacci C., Leyris A., Smagghe P.O., Tribolet S., Vacheron M.N., Viala A., Caroli F. Neuroleptic-resistant schizophrenic patients treated by clozapine: Clinical evolution, plasma and red blood cell clozapine and desmethylclozapine levels. Therapie. 52:1997;227-232.
2. Baker I., Masserano J., Wyatt R.J. Serum cytokine concentrations in patients with schizophrenia. Schizophr. Res. 20:1996;199-203.
3. Bessler H., Levental Z., Karp L., Modai I., Djaldetti M., Weizman A. Cytokine production in drug-free and neuroleptic-treated schizophrenic patients. Biol. Psychiatry. 38:1995;297-302.
4. Centorrino F.C., Baldessarni R.J., Kando J.C., Frankenburg F.R., Volpicelli S.A., Flood J.G. Clozapine and metabolites: concentrations in serum and clinical findings during the treatment of chronically psychotic patients. J. Psychopharmacol. 14:1994;119-125.
5. Chang W.H., Lin S.K., Lane H.Y., Hu W.H., Jann M.W., Lin H.N. Clozapine dosages and plasma drug concentrations. J. Formos. Med. Assoc. 96:1997;599-605.
6. Chengappa K.N., Ganguli R., Yang Z.W., Shurin G., Brar J.S., Rabin B.S. Impaired mitogen (PHA) responsiveness and increased autoantibodies in Caucasian schizophrenic patients with the HLA B8/DR3 phenotype. Biol. Psychiatry. 37:1995;546-549.
7. Davis J.M., Schaffer C.B., Killian G.A., Kinard C., Chan C. Important issues in the drug treatment of schizophrenia. Schizophr. Bull. 6:1980;70-87.
8. De Groote D., Zangerle P.F., Gevaert Y., Fassotte M.F., Beguin Y., Noizat-Pirenne F., Pirenne J., Gathy R., Lopez M., Dehart I., Igot D., Baudrihaye M., Delacroix D., Franchimont P. Direct stimulation of cytokines (IL-1β, TNF-α, IL-6, IL-2, IFN-γ and GM-CSF) in whole blood. I. Comparison with isolated PBMC stimulation. Cytokine. 4:1992;239-248.
9. DeLisi L.E., King A.C., Targum S. Serum immunoglobulin concentrations in patients admitted to an acute psychiatric in-patient service. Br. J. Psychiatry. 145:1985;661-665.
10. Dumortier G., Lochu A., Zerrouk A., Van Nieuwenhuyse V., Colen de Melo P., Roche Rabreau D., Degrassat K. Whole saliva and plasma levels of clozapine and desmethylclozapine. J. Clin. Pharm. Ther. 23:1998;35-40.
11. Freed W.J. The therapeutic latency of neuroleptic drugs and nonspecific postjunctional supersensitivity. Schizophr. Bull. 14:1988;269-277.
12. Frommberger U.H., Bauer J., Haselbauer P., Fraulin A., Riemann D., Berger M. Interleukin-6-(IL-6) plasma levels in depression and schizophrenia: comparison between the acute state and after remission. Eur. Arch. Psychiatr. Clin. Neurosci. 247:1997;228-233.
13. Gutierrez E.G., Banks W.A., Kastin A.J. Blood-born interleukin-1 receptor antagonist crosses the blood-brain barrier. J. Neuroimmunol. 55:1994;135-160.
14. Katsikis P.D., Cohen S.B., Londei M., Feldmann M. Are CD4+ Th1 cells pro-inflammatory or anti-inflammatory? The ratio of IL-10 to IFN-gamma or IL-2 determines their function. Int. Immunol. 7:1995;1287-1294.
15. Kirch D.G. Infection and autoimmunity as etiologic factors in schizophrenia: a review and reappraisal. Schizophr. Bull. 19:1993;355-370.
16. Lane H.Y., Lin H.N., Hwu H.G., Jann M., Hu W.H., Chang W.H. Haloperidol plasma concentrations in Taiwanese psychiatric patients. J. Formosan Med. Assoc. 94:1995;671-678.
17. Lane H.Y., Chang Y.C., Chang W.H., Lin S.K., Tseng Y.T., Jann M.W. Effects of gender and age on plasma levels of clozapine and its metabolites: analyzed by critical statistics. J. Clin. Psychiatry. 60:1999;36-40.
18. Leykin I., Mayer R., Shinitzky M. Short and long term immunosuppressive effects of clozapine and haloperidol. Immunopharmacology. 37:1997;75-86.
19. Lin A., Kenis G., Bignotti S., Tura G.J., DeJong R., Bosmans E., Pioli R., Altamura C., Scharpé S., Maes M. The inflammatory response system in treatment-resistant schizophrenia: increased serum interleukin-6. Schizophr. Res. 32:1998;9-15.
20. Lin A., Song C., Kenis G., Bosmans E., DeJongh R., Scharpe S., Maes M. The in vitro immunosuppressive effects of moclobemide. J. Affect. Disord. 1999;. in press.
21. Maes M., Meltzer H.Y., Bosmans E. Immune-inflammatory markers in schizophrenia: comparison to normal controls and effects of clozapine. Acta Psychiatr. Scand. 89:1994;346-351.
22. Maes M., Bosmans E., Calabrese J., Smith R., Meltzer H.Y. Interleukin-2 and interleukin-6 in schizophrenia and mania: effects of neuroleptics and mood stabilizers. J. Psychiatr. Res. 29:1995;141-152.
23. Maes M., Bosmans E., Ranjan R., Vandoolaeghe E., Meltzer H.Y., DeLey M., Bergmans R., Stans G., Desnyder R. Lower plasma CC16, a natural anti-inflammatory protein and increased plasma interleukin-1-receptor-antagonist in schizophrenia. Schizophr. Res. 21:1996;39-50.
24. Maes M., Bosmans E., Kenis G., DeJong R., Smith R.S., Meltzer H.Y. In vivo immunomodulatory effects of clozapine in schizophrenia. Schizophr. Res. 26:1997;221-225.
25. Maes M., Song C., Lin A., Bonaccorso S., Scharpe S., Kenis G., Bosmans E. Anti-inflammatory effects of antidepressants: increased production of interleukin-10 and suppressed production of interferon-gamma. Neuropsychopharmacology. 20:1999;370-379.
26. Maes M., Song C., Lin A., Pioli R., Kenis G., Kubera M., Bosmans E. In vitro immuno-regulatory effects of lithium in healthy volunteers. Psychopharmacology. 143:1999;401-407.
27. Meltzer H.Y. The mechanism of action of clozapine in relation to its clinical advantages. Meltzer H.Y., Novel Antipsychotic Drugs. 1992;1-13 Raven Press, New York.
28. Mengozzi M., Fantuzzi G., Faggioni R., Marchant A., Goldman M., Orencole S., Clark B.D., Sironi M., Benigni F., Ghezzi P. Chlorpromazine specifically inhibits peripheral and brain TNF production and up-regulates IL-10 production, in mice. Immunology. 82:1994;207-210.
29. Monteleone P., Fabrazzo M., Tortorella A., Maj M. Plasma levels of interleukin-6 and tumor necrosis factor alpha in chronic schizophrenia: effects of clozapine treatment. Psychiatr. Res. 71:1997;11-17.
30. Muller N., Hofschuster E., Ackenheil M., Eckstein R. T-cells and psychopathology in schizophrenia: relationship to the outcome of neuroleptic therapy. Acta Psychiatr. Scand. 87:1993;66-71.
31. Muller N., Empl M., Riedel M., Schwarz M., Ackenheil M. Neuroleptic treatment increases soluble IL-2 receptors and decreases soluble IL-6 receptors in schizophrenia. Eur. Arch. Psychiatr. Clin. Neurosci. 247:1997;308-313.
32. Naudin J., Mege J.L., Azorin J.M., Dassa D. Elevated circulating levels of IL-6 in schizophrenia. Schizophr. Res. 20:1996;269-273.
33. Piscitelli S.C., Frazier J.A., McKenna K., Albus K.E., Grothe D.R., Gordon C.T., Rapoport J.L. Plasma clozapine and haloperidol concentrations in adolescents with childhood-onset schizophrenia: association with response. J. Clin. Psychiatry. 55:1994;94-97.
34. Pollmacher T., Hinze-Selch D., Mullington J. Effects of clozapine on plasma cytokine and soluble cytokine receptor levels. J. Clin. Psychopharmacol. 16:1996;403-409.
35. Portoles A., Ojeda G., Portoles M.P., Rojo J.M. Effects of several neuroleptic compounds on the blastogenic response of spleen cells from mice. Int. J. Tiss. React. 4:1982;133-140.
36. Relton J.K., Rothwell N.J. Interleukin-1 receptor antagonist inhibits ischemic and excitatory neuronal damage in the rat. Brain Res. Bull. 29:1992;243-246.
37. Shintani F., Nakaki T., Kanba S., Sato K., Yagi G., Shiozawa M., Aiso S., Kato R., Asai M. Involvement of interleukin-1 in immobilization stress-induced increase in plasma adrenocoticotropic hormone and in release f hypothalamic monoamines in the rat. J. Neurosci. 15:1995;1961-1970.
38. Sirota P., Schild K., Elizur A., Djaldetti M., Fishman P. Increased interleukin-1 and interleukin-3 like activity in schizophrenic patients. Prog. Neuropsychopharmacol. Biol. Psychiatry. 19:1995;75-83.
39. Suzuki E., Shintani F., Kanba S., Asai M., Nakaki T. Induction of interleukin-1 beta and interleukin-1 receptor antagonist mRNA by chronic treatment with various psychotropics in widespread area of rat brain. Neurosci. Lett. 215:1996;201-204.
40. Tarazona R., Gonzalez-Garcia A., Zamzami N., Marchetti P., Frechin N., Gonzalo J.A., Ruiz-Gayo M., van Rooijen N., Martinez C., Kroemer G. Chlorpromazine amplifies macrophage-dependent IL-10 production in vivo. J. Immunol. 154:1995;861-870.
41. Wilke I., Arolt V., Rothermundt M., Weitzsch C., Hornberg M., Kirchner H. Investigation of cytokine production in whole blood cultures of paranoid and residual schizophrenic patients. Eur. Arch. Psychiatr. Clin. Neurosci. 246:1996;279-284.
42. Zangerle P.F., De Groote D., Lopez M., Meuleman R.J., Vrindts Y., Fauchet F., Dehart I., Jadoul M., Radoux D., Franchimont P. Direct stimulation of cytokines (IL-1 beta, TNF-alpha, IL-6, IL-2, IFN-gamma and GM-CSF) in whole blood: II. Application to rheumatoid arthritis and osteoarthritis. Cytokine. 4:1992;568-575.